Constipation - Pipeline Insight, 2024

This “Constipation- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Constipation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Constipation: Understanding

Constipation: Overview

Constipation is a condition in which you may have fewer than three bowel movements a week; stools that are hard, dry, or lumpy; stools that are difficult or painful to pass; or a feeling that not all stool has passed. In many patients, constipation is associated with sluggish movement of stool through the colon. This delay may be due to drugs, organic conditions, or a disorder of defecatory function (ie, pelvic floor dysfunction), or a disorder that results from diet. Certain findings raise suspicion of a more serious etiology of chronic constipation: Distended, tympanitic abdomen, vomiting, blood in stool, weight loss and severe constipation of recent onset/worsening in older patients. Chronic constipation with modest abdominal discomfort in a patient who has used laxatives for a long time suggests slow-transit constipation. Acute constipation coincident with the start of a constipating drug in patients without red flag findings suggests the drug is the cause. New-onset constipation that persists for weeks or occurs intermittently with increasing frequency or severity, in the absence of a known cause, suggests colonic tumor or other causes of partial obstruction. Excessive straining or prolonged or unsatisfactory defecation, with or without anal digitation, suggests a defecatory disorder. Patients with fecal impaction may have cramps and may pass watery mucus or fecal material around the impacted mass, mimicking diarrhea (overflow diarrhea). Patients with chronic constipation who do not meet the criteria for IBS may have functional constipation. Constipation with a clear etiology (drugs, trauma, bed rest) may be treated symptomatically without further study. Patients with symptoms of bowel obstruction require flat and upright abdominal x-rays, possibly a water-soluble contrast enema to evaluate for colonic obstruction, and possibly a CT scan or barium x-ray of the small intestine. Most patients without a clear etiology should have colonoscopy and a laboratory evaluation (complete blood count, thyroid-stimulating hormone, fasting glucose, electrolytes, and calcium). Constipation is common among older people because of low-fiber diets, lack of exercise, coexisting medical conditions, and use of constipating drugs. Many older people have misconceptions about normal bowel habits and use laxatives regularly. Other changes that predispose older people to constipation include increased rectal compliance and impaired rectal sensation (such that larger rectal volumes are needed to elicit the desire to defecate).

“Constipation- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Constipation pipeline landscape is provided which includes the disease overview and Constipation treatment guidelines. The assessment part of the report embraces, in depth Constipation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Constipation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Constipation R&D. The therapies under development are focused on novel approaches to treat/improve Constipation.

Constipation Emerging Drugs Chapters

This segment of the Constipation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Constipation Emerging Drugs

Pradigastat : Anji Pharma ANJ908 (Pradigastat) has the potential to markedly improve treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome-associated constipation (IBS-C), two prevalent diseases with few effective treatments. The inhibition of DGAT1 by ANJ908 changes the intestinal milieu, namely by raising the level of fatty acids in the gut lumen. This leads to increased colon motility and water secretion, two necessary attributes for effective constipation therapy. Anji has initiated a Phase 2 trial of ANJ908 (pradigastat) in patients with functionalconstipation.

YH 12852 : Yuhan YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients with Functional Constipation. Currently, the drug is in Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients with FunctionalConstipation.

RQ 00000010 : Ra Qualia Pharma RQ-00000010 is a highly-selective serotonin receptor subtype 5HT4 partial-agonist that promotes the motility of the gastrointestinal (GI) tract. With Phase 1 clinical trials of this compound completed, the compound's superior safety, tolerability, and pharmacokinetic profiles have also been confirmed as expected, with its powerful efficacy in accelerating gastric emptying in humans clearly demonstrated as well. Based on these characteristics, the compound is seen as a promising therapeutic agent for functional gastrointestinal disorders such as gastroparesis and functional dyspepsia, as well as for chronic constipation and otherindications.

RQ 00433412 : Ra Qualia Pharma RQ-00433412 is a novel small molecule having a ghrelin receptor agonistic activity. RQ-00433412 exhibited highly selective and potent agonistic activity against the human ghrelin receptor. RQ-00433412 induced defecation in chronic spinal cord-injured rats without increasing the fecal water content, showing no desensitization following repeated treatment. These profiles suggest a therapeutic potential of RQ-00433412 for constipation in SCI patients with low risk of unplanned bowel evacuation/incontinence. Currently, the drug is in pre-clinical stage ofdevelopment.

Constipation: Therapeutic Assessment

This segment of the report provides insights about the different Constipation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Constipation

There are approx. 20+ key companies which are developing the therapies for Constipation. The companies which have their Constipation drug candidates in the most advanced stage, i.e. phase II include, Anji Pharma.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Constipation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Constipation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Constipation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Constipation drugs.

Constipation Report Insights

• Constipation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Constipation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Constipation drugs?
• How many Constipation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Constipation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Constipation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Constipation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Anji Pharma
• Yuhan
• Theravance Biopharma
• Ra QualiaPharma
• Processa Pharmaceuticals
• Abbott
• AbbVie`s Inc.
• Albireo Pharma, Inc.
• AstraZeneca
• Bausch Health Companies Inc.
• Bayer AG
• Cosmo Pharma

Key Products

• RQ 00433412
• Pradigastat
• YH 12852
• RQ 00000010
• Limosilactobacillus reuteri
• SVT 1B149
• VS013

This product will be delivered within 1-3 business days.